BioSpace News Archive

Theravance Biopharma, Inc. announced its 2022 Accomplishments and 2023 Key Targets.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided updated financial guidance for full year 2022 and announced financial guidance for full year 2023.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced the availability of a state-of-the-art research use only offering for biopharmaceutical companies.

ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, announced the expansion of their leadership team through the appointment of Robert MacLeod, Ph.D. as Chief Scientific Officer.

Affimed N.V. announced that the U.S. Food and Drug Administration has issued a written response to the Company’s pre-IND meeting request for the AFM13 and Artiva Biotherapeutics, Inc. ’s AB-101 co-administered combination therapy in relapsed/refractory Hodgkin lymphoma and the exploratory arm evaluating the combination in r/r CD30-positive peripheral T-cell lymphoma.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, will present at the 41st Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT, and a live webcast will be available at ir.springworkstx.com.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present tomorrow, Tuesday, January 10 at 8:15 a.m. PT/11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare Conference.

Caris Life Sciences® and ConcertAI announced a unique partnership to align the two companies’ oncology capabilities.

RVL Pharmaceuticals plc, a specialty pharmaceutical company, announced preliminary fourth quarter and full year 2022 net product sales of UPNEEQ®, 0.1%, the first and only U.S. Food and Drug Administration -approved ophthalmic solution for blepharoptosis, or droopy eyelids, of approximately $12.1 million and $36.5 million, respectively.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec have announced Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for Mpox virus detection.